Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/2936/2/17: Health professional consultant v Johnson & Johnson – Online Nicorette advertisement (No breach)

Complaint about a Nicorette online ad: use of an infant image and a β€œ43% more effective” claim without…

8 Mar 2026

AUTH/2053/10/07: GlaxoSmithKline v AstraZeneca – Symbicort SMART leavepiece (no breach)

GSK challenged an AstraZeneca Symbicort SMART leavepiece for an unqualified β€˜Rx… plus as needed’ dosing line. The Panel…

8 Mar 2026

ProStrakan press release on Rectogesic: β€˜aiding healing’ claim ruled inaccurate (Clauses 9.1, 20.2); no promotion breach

A public complaint challenged a Rectogesic press release implying it aided fissure healing. PMCPA ruled the statement inaccurate…

8 Mar 2026

Anonymous v Merck Sharp & Dohme: Cerazette Discount Scheme (AUTH/2613/6/13)

PMCPA case AUTH/2613/6/13 about a Cerazette discount scheme. The matter was found to be outwith the scope of…

8 Mar 2026

GSK voluntary admission: out-of-date prescribing information used in Avandamet ads (AUTH/1922/11/06)

GSK disclosed that Avandamet ads ran for ~3 months with outdated prescribing information omitting macular oedema as a…

8 Mar 2026

Biogen Idec: Imraldi aRMMs sent by recorded delivery to a doctor’s home address (AUTH/3121/11/18)

A hospital doctor said an Imraldi mailing requiring a signature was harassment and an inappropriate marketing practice. Panel…

8 Mar 2026

Strides Pharma: LinkedIn comment promoted POM Strivit D3 to the public (AUTH/3347/5/20)

A senior employee’s LinkedIn comment praising Strivit D3 (β€œlicensed, prescribed, kosher and halal”) was ruled to be public…

8 Mar 2026

AUTH/3445/12/20: Novo Nordisk Ozempic email alleged off-label promotion to under-18s (No breach)

Complaint said an Ozempic promotional email implied use in all type 2 diabetes patients because β€œadults” appeared later…

8 Mar 2026

Teva respiratory websites: missing PI/AE signposting online, audience separation issues, and off-label implication from guideline content (AUTH/3451/1/21)

Teva’s HCP and education websites were ruled promotional in parts. Breaches included missing prominent PI/AE signposting online, missing…

8 Mar 2026

AUTH/3592/12/21: Bayer v Janssen (Erleada on-demand promotional video) – No breach

Bayer challenged Janssen’s Erleada promotional video alleging off-licence promotion and misleading/disparaging cross-trial safety comparisons. The PMCPA Panel ruled…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training